349 related articles for article (PubMed ID: 21605657)
21. Increased neopterin production and tryptophan degradation in advanced Parkinson's disease.
Widner B; Leblhuber F; Fuchs D
J Neural Transm (Vienna); 2002 Feb; 109(2):181-9. PubMed ID: 12075858
[TBL] [Abstract][Full Text] [Related]
22. The immune-kynurenine pathway in social anxiety disorder.
Butler MI; Long-Smith C; Moloney GM; Morkl S; O'Mahony SM; Cryan JF; Clarke G; Dinan TG
Brain Behav Immun; 2022 Jan; 99():317-326. PubMed ID: 34758380
[TBL] [Abstract][Full Text] [Related]
23. Immunobiochemical pathways of neopterin formation and tryptophan breakdown via indoleamine 2,3-dioxygenase correlate with circulating tumor cells in ovarian cancer patients- A study of the OVCAD consortium.
Gostner JM; Obermayr E; Braicu IE; Concin N; Mahner S; Vanderstichele A; Sehouli J; Vergote I; Fuchs D; Zeillinger R
Gynecol Oncol; 2018 May; 149(2):371-380. PubMed ID: 29530331
[TBL] [Abstract][Full Text] [Related]
24. Probiotic Lactobacillus Plantarum 299v decreases kynurenine concentration and improves cognitive functions in patients with major depression: A double-blind, randomized, placebo controlled study.
Rudzki L; Ostrowska L; Pawlak D; Małus A; Pawlak K; Waszkiewicz N; Szulc A
Psychoneuroendocrinology; 2019 Feb; 100():213-222. PubMed ID: 30388595
[TBL] [Abstract][Full Text] [Related]
25. Positron emission tomography quantification of serotonin(1A) receptor binding in suicide attempters with major depressive disorder.
Sullivan GM; Oquendo MA; Milak M; Miller JM; Burke A; Ogden RT; Parsey RV; Mann JJ
JAMA Psychiatry; 2015 Feb; 72(2):169-78. PubMed ID: 25549105
[TBL] [Abstract][Full Text] [Related]
26. Neopterin production and tryptophan degradation during 24-months therapy with interferon beta-1a in multiple sclerosis patients.
Durastanti V; Lugaresi A; Bramanti P; Amato M; Bellantonio P; De Luca G; Picconi O; Fantozzi R; Locatelli L; Solda' A; Sessa E; Totaro R; Marino S; Zipoli V; Zorzon M; Millefiorini E
J Transl Med; 2011 Apr; 9():42. PubMed ID: 21501517
[TBL] [Abstract][Full Text] [Related]
27. Kynurenine pathway changes in late-life depression with memory deficit.
Wu Y; Mai N; Zhong X; Wen Y; Zhou Y; Li H; Shang D; Hu L; Chen X; Chen B; Zhang M; Ning Y
Psychiatry Res; 2018 Nov; 269():45-49. PubMed ID: 30145300
[TBL] [Abstract][Full Text] [Related]
28. Increased plasma levels of competing amino acids, rather than lowered plasma tryptophan levels, are associated with a non-response to treatment in major depression.
Ormstad H; Dahl J; Verkerk R; Andreassen OA; Maes M
Eur Neuropsychopharmacol; 2016 Aug; 26(8):1286-96. PubMed ID: 27237997
[TBL] [Abstract][Full Text] [Related]
29. Aggression, impulsivity and inflammatory markers as risk factors for suicidal behavior.
Coryell W; Wilcox H; Evans SJ; Pandey GN; Jones-Brando L; Dickerson F; Yolken R
J Psychiatr Res; 2018 Nov; 106():38-42. PubMed ID: 30261413
[TBL] [Abstract][Full Text] [Related]
30. Ongoing episode of major depressive disorder is not associated with elevated plasma levels of kynurenine pathway markers.
Dahl J; Andreassen OA; Verkerk R; Malt UF; Sandvik L; Brundin L; Ormstad H
Psychoneuroendocrinology; 2015 Jun; 56():12-22. PubMed ID: 25770856
[TBL] [Abstract][Full Text] [Related]
31. Non-invasive monitoring of kidney allograft rejection through IDO metabolism evaluation.
Brandacher G; Cakar F; Winkler C; Schneeberger S; Obrist P; Bösmüller C; Werner-Felmayer G; Werner ER; Bonatti H; Margreiter R; Fuchs D
Kidney Int; 2007 Jan; 71(1):60-7. PubMed ID: 17136028
[TBL] [Abstract][Full Text] [Related]
32. The role of the kynurenine pathway and quinolinic acid in adolescent major depressive disorder.
Öztürk M; Yalın Sapmaz Ş; Kandemir H; Taneli F; Aydemir Ö
Int J Clin Pract; 2021 Apr; 75(4):e13739. PubMed ID: 32997876
[TBL] [Abstract][Full Text] [Related]
33. [Diagnoses and new therapeutic strategy focused on physiological alteration of tryptophan metabolism].
Mouri A; Hasegawa M; Kunisawa K; Saito K; Nabeshima T
Nihon Yakurigaku Zasshi; 2023 May; 158(3):233-237. PubMed ID: 36990795
[TBL] [Abstract][Full Text] [Related]
34. Tryptophan via serotonin/kynurenine pathways abnormalities in a large cohort of aggressive inmates: markers for aggression.
Comai S; Bertazzo A; Vachon J; Daigle M; Toupin J; Côté G; Turecki G; Gobbi G
Prog Neuropsychopharmacol Biol Psychiatry; 2016 Oct; 70():8-16. PubMed ID: 27117820
[TBL] [Abstract][Full Text] [Related]
35. Neopterin and biopterin levels and tryptophan degradation in patients with diabetes.
Gürcü S; Girgin G; Yorulmaz G; Kılıçarslan B; Efe B; Baydar T
Sci Rep; 2020 Oct; 10(1):17025. PubMed ID: 33046801
[TBL] [Abstract][Full Text] [Related]
36. Kynurenine is correlated with IL-1β in plasma of schizophrenia patients.
Joaquim HPG; Costa AC; Gattaz WF; Talib LL
J Neural Transm (Vienna); 2018 May; 125(5):869-873. PubMed ID: 29306989
[TBL] [Abstract][Full Text] [Related]
37. Changes in the tryptophan-kynurenine axis in association to therapeutic response in clinically depressed patients undergoing psychiatric rehabilitation.
Reininghaus B; Riedrich K; Dalkner N; Bengesser SA; Birner A; Platzer M; Hamm C; Gostner JM; Fuchs D; Reininghaus EZ
Psychoneuroendocrinology; 2018 Aug; 94():25-30. PubMed ID: 29753175
[TBL] [Abstract][Full Text] [Related]
38. Changes in tryptophan metabolism during pregnancy and postpartum periods: Potential involvement in postpartum depressive symptoms.
Teshigawara T; Mouri A; Kubo H; Nakamura Y; Shiino T; Okada T; Morikawa M; Nabeshima T; Ozaki N; Yamamoto Y; Saito K
J Affect Disord; 2019 Aug; 255():168-176. PubMed ID: 31158779
[TBL] [Abstract][Full Text] [Related]
39. Tryptophan-kynurenine and lipid related metabolites as blood biomarkers for first-episode drug-naïve patients with major depressive disorder: An exploratory pilot case-control study.
Kuwano N; Kato TA; Setoyama D; Sato-Kasai M; Shimokawa N; Hayakawa K; Ohgidani M; Sagata N; Kubo H; Kishimoto J; Kang D; Kanba S
J Affect Disord; 2018 Apr; 231():74-82. PubMed ID: 29454180
[TBL] [Abstract][Full Text] [Related]
40. Associations among peripheral and central kynurenine pathway metabolites and inflammation in depression.
Haroon E; Welle JR; Woolwine BJ; Goldsmith DR; Baer W; Patel T; Felger JC; Miller AH
Neuropsychopharmacology; 2020 May; 45(6):998-1007. PubMed ID: 31940661
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
